CHRM3

Across TCGA pan-cancer cohorts, CHRM3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CHRM3 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHRM3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRM3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC and GBM are the cancer types where CHRM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.340	0.699	.024	3	view →
GBM	DFS	Median	All	0.824	0.678	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CHRM3–PDAC (DFS)

Open the PDAC breakdown →